[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012002265B8 - composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios - Google Patents

composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios

Info

Publication number
BR112012002265B8
BR112012002265B8 BR112012002265A BR112012002265A BR112012002265B8 BR 112012002265 B8 BR112012002265 B8 BR 112012002265B8 BR 112012002265 A BR112012002265 A BR 112012002265A BR 112012002265 A BR112012002265 A BR 112012002265A BR 112012002265 B8 BR112012002265 B8 BR 112012002265B8
Authority
BR
Brazil
Prior art keywords
disorders
cancer
diseases
treatment
pharmaceutical compositions
Prior art date
Application number
BR112012002265A
Other languages
English (en)
Other versions
BR112012002265B1 (pt
BR112012002265A2 (pt
Inventor
Specht Verwijs Dauntel
Sophie Tobias Irene
D Skwierczynski Raymond
Ramanan Vijayalakshmi
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012002265(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR112012002265A2 publication Critical patent/BR112012002265A2/pt
Publication of BR112012002265B1 publication Critical patent/BR112012002265B1/pt
Publication of BR112012002265B8 publication Critical patent/BR112012002265B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios. esta invenção fornece novas composições farmacêuticas do composto da fórmula (i): ou um sal farmaceuticamente aceitável do mesmo, que são adequadas para a produção em massa de uma forma de dosagem farmacêutica oral; processos para a produção da dita forma de dosagem farmacêutica oral; e o uso da composição farmacêutica para o tratamento de pacientes que sofrem de, ou estão sujeitos a, doenças, distúrbios, ou condições envolvendo a sobrevivência, proliferação e migração celular, incluindo distúrbios proliferativos inflamatórios crônicos, distúrbios oculares proliferativos, distúrbios proliferativos benignos e câncer.
BR112012002265A 2009-07-31 2010-07-28 composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios BR112012002265B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
US61/230,212 2009-07-31
PCT/US2010/002109 WO2011014248A1 (en) 2009-07-31 2010-07-28 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders

Publications (3)

Publication Number Publication Date
BR112012002265A2 BR112012002265A2 (pt) 2016-06-14
BR112012002265B1 BR112012002265B1 (pt) 2021-01-12
BR112012002265B8 true BR112012002265B8 (pt) 2021-05-25

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002265A BR112012002265B8 (pt) 2009-07-31 2010-07-28 composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios

Country Status (30)

Country Link
US (3) US20110039826A1 (pt)
EP (1) EP2459173B1 (pt)
JP (2) JP2013500965A (pt)
KR (1) KR101762285B1 (pt)
CN (2) CN103893186B (pt)
AR (1) AR077436A1 (pt)
AU (1) AU2010276741B2 (pt)
BR (1) BR112012002265B8 (pt)
CA (1) CA2769531C (pt)
CL (1) CL2012000261A1 (pt)
CO (1) CO6612185A2 (pt)
CR (1) CR20120084A (pt)
EA (1) EA025277B1 (pt)
EC (1) ECSP12011703A (pt)
GE (1) GEP201606513B (pt)
IL (1) IL217839A (pt)
IN (1) IN2012DN01237A (pt)
JO (1) JO3434B1 (pt)
MA (1) MA33533B1 (pt)
MX (2) MX348197B (pt)
MY (1) MY174084A (pt)
NZ (1) NZ598096A (pt)
PE (1) PE20120788A1 (pt)
SG (2) SG177751A1 (pt)
TN (1) TN2012000046A1 (pt)
TW (1) TWI522357B (pt)
UA (1) UA110463C2 (pt)
UY (1) UY32822A (pt)
WO (1) WO2011014248A1 (pt)
ZA (1) ZA201200944B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139355A (en) * 2004-05-14 2009-09-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
JP2013520424A (ja) 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
MXPA02001398A (es) 1999-08-11 2002-08-12 Idec Pharma Corp Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20.
AR027715A1 (es) * 2000-03-24 2003-04-09 Baker Norton Pharma Composiciones basadas en taxanos y metodos de uso de las mismas
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
MY139355A (en) * 2004-05-14 2009-09-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
WO2007076348A2 (en) * 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
CA2657346A1 (en) * 2006-07-21 2008-01-24 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
US7718648B2 (en) * 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) * 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形

Also Published As

Publication number Publication date
JP2013500965A (ja) 2013-01-10
US9504693B2 (en) 2016-11-29
NZ598096A (en) 2014-05-30
CA2769531A1 (en) 2011-02-03
TN2012000046A1 (en) 2013-09-19
CN103893186A (zh) 2014-07-02
SG10201404483VA (en) 2014-10-30
CR20120084A (es) 2012-06-01
CO6612185A2 (es) 2013-02-01
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
CL2012000261A1 (es) 2012-08-03
MY174084A (en) 2020-03-09
AR077436A1 (es) 2011-08-24
SG177751A1 (en) 2012-02-28
MA33533B1 (fr) 2012-08-01
IL217839A (en) 2017-01-31
JP2015091877A (ja) 2015-05-14
TW201107331A (en) 2011-03-01
CN102548539A (zh) 2012-07-04
WO2011014248A1 (en) 2011-02-03
IN2012DN01237A (pt) 2015-05-15
JP6014695B2 (ja) 2016-10-25
TWI522357B (zh) 2016-02-21
JO3434B1 (ar) 2019-10-20
EP2459173A1 (en) 2012-06-06
PE20120788A1 (es) 2012-07-22
EA025277B1 (ru) 2016-12-30
ZA201200944B (en) 2015-07-29
US9127011B2 (en) 2015-09-08
KR20120053008A (ko) 2012-05-24
IL217839A0 (en) 2012-03-29
CA2769531C (en) 2017-11-07
MX2012001196A (es) 2012-03-14
AU2010276741A1 (en) 2012-03-01
US20110039826A1 (en) 2011-02-17
MX348197B (es) 2017-06-05
EA201270205A1 (ru) 2012-07-30
EP2459173B1 (en) 2018-02-28
AU2010276741B2 (en) 2016-07-14
ECSP12011703A (es) 2012-03-30
BR112012002265A2 (pt) 2016-06-14
UA110463C2 (ru) 2016-01-12
GEP201606513B (en) 2016-07-25
KR101762285B1 (ko) 2017-07-28
US20160158244A1 (en) 2016-06-09
US20140073630A1 (en) 2014-03-13
UY32822A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
BR112012002265B8 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
IN2014MN00988A (pt)
BR112012013431A8 (pt) composto, composição farmacêutica e seu uso
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2013012588A (es) Inhibidores de cinasa.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
BR112014004447A2 (pt) bifenilcarboxamidas como inibidores de quinase rock
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
CL2008002696A1 (es) Compuestos derivados de hidroxi-benzamidas, antagonistas de receptores muscarinicos; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; y uso del compuesto para el tratamiento de enfermedades de las vias respiratorias obstructivas o inflamatorias, broncoconstriccion, asma, bronquitis.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF